Gemeprost
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Routes of administration | Pessary |
ATC code | G02AD03 (WHO) |
Identifiers | |
| |
Synonyms | methyl (E)-7-[(1R,2S,3R)-3-hydroxy-2-[(E,3R)-3-hydroxy-4,4-dimethyl-oct-1-enyl]-5-oxo-cyclopentyl]hept-2-enoate |
CAS Number | 64318-79-2 |
PubChem (CID) | 5282237 |
DrugBank | DB08964 |
ChemSpider | 4445416 |
UNII | 45KZB1FOLS |
KEGG | D02073 |
ECHA InfoCard | 100.058.869 |
Chemical and physical data | |
Formula | C23H38O5 |
Molar mass | 394.545 g/mol |
3D model (Jmol) | Interactive image |
| |
| |
(what is this?) (verify) |
Gemeprost (16, 16-dimethyl-trans-delta2 PGE1 methyl ester) is an analogue of prostaglandin E1.
Clinical use
It is used as a treatment for obstetric bleeding.
It is used with mifepristone to terminate pregnancy up to 24 weeks gestation.[1]
Side effects
Vaginal bleeding, cramps, nausea, vomiting, loose stools or diarrhea, headache, muscle weakness; dizziness; flushing; chills; backache; dyspnoea; chest pain; palpitations and mild pyrexia. Rare: Uterine rupture, severe hypotension, coronary spasms with subsequent myocardial infarctions.
References
- ↑ Bartley J, Brown A, Elton R, Baird DT (October 2001). "Double-blind randomized trial of mifepristone in combination with vaginal gemeprost or misoprostol for induction of abortion up to 63 days gestation". Human reproduction (Oxford, England). 16 (10): 2098–102. doi:10.1093/humrep/16.10.2098. PMID 11574498. Retrieved 2008-10-29.
This article is issued from Wikipedia - version of the 5/31/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.